Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Miami, FL
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Orlando, FL
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Stockbridge, GA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Stockbridge, GA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Overland Park, KA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Monroe, LA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Monroe, LA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Worcester, MA
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Albuquerque, NM
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Brooklyn, NY
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
New York, NY
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Investigator Sie
mi
from
Charleston, SC
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Investigator Sie
mi
from
Charleston, SC
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Memphis, TN
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Clinical Research Facility
mi
from
Mesquite, TX
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  9/5/2017
Investigational Site
mi
from
Brussels,
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 9/5/2017
Investigational Site
mi
from
Brussels,
Click here to add this to my saved trials
Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint
Botulinum Toxin Versus Steroid Injection for Basal Joint Arthritis of the Thumb: a Randomized, Double Blind, Placebo-controlled Clinical Trial
Status: Enrolling
Updated:  9/7/2017
University of Missouri
mi
from
Columbia, MO
Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint
Botulinum Toxin Versus Steroid Injection for Basal Joint Arthritis of the Thumb: a Randomized, Double Blind, Placebo-controlled Clinical Trial
Status: Enrolling
Updated: 9/7/2017
University of Missouri
mi
from
Columbia, MO
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Alabama Orthopaedic Center - Research
mi
from
Birmingham, AL
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Alabama Orthopaedic Center - Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
HOPE Research Institute
mi
from
Phoenix, AZ
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
HOPE Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Tucson Orthopaedic Institute
mi
from
Tucson, AZ
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Tucson Orthopaedic Institute
mi
from
Tucson, AZ
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Orthoarkansas
mi
from
Little Rock, AR
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Orthoarkansas
mi
from
Little Rock, AR
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Advent Clinical Research
mi
from
Pinellas Park, FL
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Advent Clinical Research
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Rockford Orthopedic Associates, LTD
mi
from
Rockford, IL
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Rockford Orthopedic Associates, LTD
mi
from
Rockford, IL
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
The Indiana Hand to Shoulder Center
mi
from
Indianapolis, IN
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
The Indiana Hand to Shoulder Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Stony Brook University Medical Center
mi
from
Stony Brook, NY
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
David R. Mandel, MD, Inc.
mi
from
Cleveland, OH
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
David R. Mandel, MD, Inc.
mi
from
Cleveland, OH
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Health Research Institute
mi
from
Oklahoma City, OK
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Health Research Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Blair Orthopedic Associates, Inc.
mi
from
Altoona, PA
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Blair Orthopedic Associates, Inc.
mi
from
Altoona, PA
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Basin Orthopedic Surgical Specialists
mi
from
Odessa, TX
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Basin Orthopedic Surgical Specialists
mi
from
Odessa, TX
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Core Orthopaedic Medical Center
mi
from
Encinitas, CA
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Core Orthopaedic Medical Center
mi
from
Encinitas, CA
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
TriWest Research Associates
mi
from
La Mesa, CA
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
TriWest Research Associates
mi
from
La Mesa, CA
Click here to add this to my saved trials
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Alpha Clinical Research
mi
from
Clarksville, TN
AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Alpha Clinical Research
mi
from
Clarksville, TN
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Little Rock, AR
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
San Francisco, CA
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Aurora, CO
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
West Palm Beach, FL
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Augusta, GA
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Chicago, IL
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Omaha, NE
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Brooklyn, NY
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
New Hyde Park, NY
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
New York, NY
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Cincinnati, OH
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Cleveland, OH
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Toledo, OH
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Philadelphia, PA
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Memphis, TN
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
Clinical Research Facility
mi
from
Fairfax, VA
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated:  9/7/2017
mi
from
Washington, D.C.,
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)
Status: Enrolling
Updated: 9/7/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Alabama Orthopaedic Center - Research
mi
from
Birmingham, AL
Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Alabama Orthopaedic Center - Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Coastal Clinical Research Inc
mi
from
Mobile, AL
Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Coastal Clinical Research Inc
mi
from
Mobile, AL
Click here to add this to my saved trials
Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated:  9/7/2017
Arizona Research Center
mi
from
Phoenix, AZ
Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
Status: Enrolling
Updated: 9/7/2017
Arizona Research Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials